Treatment with with oestrogens of primary hyperparathyroidism in post-menopausal women.

Suppr

超能文献

作者信息

Gallagher J C, Nordin B E

出版信息

Lancet. 1972 Mar 4;1(7749):503-7. doi: 10.1016/s0140-6736(72)90173-0.

DOI:10.1016/s0140-6736(72)90173-0

PMID:4110019

Abstract

摘要

相似文献

Treatment with with oestrogens of primary hyperparathyroidism in post-menopausal women.

Lancet. 1972 Mar 4;1(7749):503-7. doi: 10.1016/s0140-6736(72)90173-0.

The effect of ethinyloestradiol on calcium and phosphorus metabolism of post-menopausal women with primary hyperparathyroidism.

Clin Sci Mol Med. 1973 Dec;45(6):785-802. doi: 10.1042/cs0450785.

Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women.

N Engl J Med. 1986 Jun 5;314(23):1481-5. doi: 10.1056/NEJM198606053142304.

Effects of oestrogen and progestogen therapy on calcium metabolism in post-menopausal women.

Front Horm Res. 1975;3:150-76. doi: 10.1159/000398273.

The crush fracture syndrome in postmenopausal women.

Clin Endocrinol Metab. 1973 Jul;2(2):293-315. doi: 10.1016/s0300-595x(73)80045-3.

The effect of 1alpha-hydroxycholecalciferol and hormone therapy on the calcium balance of post-menopausal osteoporosis.

Calcif Tissue Res. 1977 May;22 Suppl:78-84. doi: 10.1007/BF02064045.

Some effects of ethinyl oestradiol on calcium and phosphorus metabolism in osteoporosis.

Clin Sci. 1968 Jun;34(3):411-7.

Biochemical effects of a calcium supplement in postmenopausal women with primary hyperparathyroidism.

Horm Metab Res. 1994 Jan;26(1):39-42. doi: 10.1055/s-2007-1000769.

SPINAL OSTEOPOROSIS AND THE MENOPAUSE.

Proc R Soc Med. 1965 Jun;58(6):441-4. doi: 10.1177/003591576505800622.

[Cytologic examination of vaginal smears in postmenopausal women undergoing ethinyl estradiol treatment].

Nord Med. 1968 Mar 21;79(12):385-8.

引用本文的文献

Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes.

Endocr Rev. 2025 Jul 15;46(4):576-620. doi: 10.1210/endrev/bnaf010.

A bioassay for parathyroid hormone and other substances affecting bone metabolism.

Ir J Med Sci. 1976 Dec;145(1):319. doi: 10.1007/BF02938966.

Normocalcemic primary hyperparathyroidism.

J Clin Densitom. 2013 Jan-Mar;16(1):33-9. doi: 10.1016/j.jocd.2012.12.001.

Bone turnover markers in primary hyperparathyroidism.

J Clin Densitom. 2013 Jan-Mar;16(1):22-7. doi: 10.1016/j.jocd.2012.11.004.

Current pharmacological options for the management of primary hyperparathyroidism.

Drugs. 2006;66(17):2189-211. doi: 10.2165/00003495-200666170-00004.

Hyperparathyroidism in the elderly patient.

Drugs Aging. 2004;21(15):1013-24. doi: 10.2165/00002512-200421150-00004.

Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.

World J Surg. 2004 Dec;28(12):1293-7. doi: 10.1007/s00268-004-7611-1. Epub 2004 Nov 11.

Diagnosis and treatment of hyperparathyroidism.

Rev Endocr Metab Disord. 2000 Nov;1(4):247-52. doi: 10.1023/a:1026545813468.

"Asymptomatic" and symptomatic primary hyperparathyroidism.

Clin Investig. 1993 Jul;71(7):505-18. doi: 10.1007/BF00208472.

Effect of estrogens and phosphorus depletion on plasma calcitonin in the rat.

Calcif Tissue Int. 1983 Jul;35(4-5):502-7. doi: 10.1007/BF02405084.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验